Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 31 of 6351
-
Phone alerts and therapy sessions aim to prevent suicide after hospital discharge
Symptom relief Not yet recruitingThe goal of this clinical trial is to learn whether a combination of brief digital and clinician-delivered interventions can help adults leaving a psychiatric hospitalization cope with suicidal thoughts and prevent suicide-related events. The main questions it aims to answer are…
Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Aug 05, 2026 00:00 UTC
-
Could your own fat cells fight Alzheimer's? new trial aims to find out
Disease control Not yet recruitingThe goal of this Phase 2 clinical trial is to learn if repeated dosing of RB-ADSC (an investigational autologous cell product obtained from participant's own adipose tissue) enhances the positive preliminary results seen in Phase 1 for the of treatment for mild to moderate Alzhei…
Phase 2 • Sponsor: Regeneration Biomedical, Inc. • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New malaria combo aims to stop relapses for good
Cure Not yet recruitingThe goal of this Phase 2b study is to examine the safety and efficacy of the combination of SJ733, an investigational agent, and tafenoquine for the radical cure of uncomplicated P. vivax malaria monoinfection in adult participants and determine the contributions of SJ733 to the …
Phase 2 • Sponsor: R. Kiplin Guy • Aim: Cure
Last updated Aug 01, 2026 00:00 UTC
-
Mouthwash for moms: simple oral care could save thousands of tiny newborns
Prevention Not yet recruitingPeriodontal disease in pregnant women has been implicated as a potential risk factor for adverse pregnancy outcomes, including being born preterm, small-for-gestational age, and/or low birth weight. Infants who have at least one of these outcomes, known as small vulnerable newbor…
Phase 3 • Sponsor: Johns Hopkins Bloomberg School of Public Health • Aim: Prevention
Last updated Jul 11, 2026 00:00 UTC
-
Triple attack on lung scarring: could plasma exchange and immune therapy slow IPF?
Disease control Not yet recruitingThis Phase IIb trial will compare effectiveness and safety of a multi-component autoantibody reduction therapy (AART), consisting of therapeutic plasma exchange (TPE), rituximab, and intravenous immunoglobulin (IVIg) for treatment of patients with progressive idiopathic pulmonary…
Phase 2 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Double-Pronged immune cells take aim at stubborn blood cancers
Disease control Not yet recruitingTo determine the safety, toxicity, and maximum tolerated dose (MTD) of CD19/CD20 bispecific CAR-T cells with 4-1BB and mutated CD28 costimulatory domains (20-19 Tan BB06z) in patients with relapsed or refractory CD19+ aggressive hematologic malignancies
Phase 1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
AI-Powered surveillance may outsmart liver cancer recurrence
Disease control Not yet recruitingHepatocellular carcinoma, the most common type of primary liver cancer, can recur after liver resection or thermal ablation performed with curative intent. Follow-up imaging is commonly scheduled at fixed intervals, although the risk of recurrence differs among patients and may c…
Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Can a Two-Drug combo wipe out hidden leukemia cells?
Disease control Recruiting nowThis phase II trial tests the effect of venetoclax in combination with standard of care (SOC) zanubrutinib in treating patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) in…
Phase 2 • Sponsor: Kerry Rogers • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can a biomarker spare breast cancer patients from harsh chemo?
Disease control Recruiting nowThis study tests a new treatment approach for people with early-stage triple negative breast cancer whose tumors have a high number of immune cells, called tumor-infiltrating lymphocytes or TILs, as seen by a pathologist on tissue review. A high TIL count is a sign the cancer may…
Phase 2 • Sponsor: Medical University of South Carolina • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
A shot at safer CAR t: early brain protection for lymphoma patients?
Disease control Not yet recruitingThe goal of this clinical trial is to reduce the duration of ICANS and incidence of G3 or great ICANS in participants who receive axi-cel. The main questions the study aims to answer are: Efficacy of IT therapy to reduce high-grade ICANS in participants who receive axi-cel in NHL…
Phase 2 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Can a One-Two punch of immunotherapy and radiation wipe out head and neck tumors before surgery?
Disease control Not yet recruitingThis is a non-comparative randomized Phase 2 study using the INITIUM regimen with or without elective nodal irradiation (ENI) delivered before surgery for resectable head and neck squamous cell carcinoma (HNSCC).
Phase 2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Can a Four-Drug combo tackle a tough liver cancer?
Disease control Not yet recruitingThe purpose of this study is to learn how well a combination of iparomlimab and tuvonralimab (QL1706), lenvatinib, radiotherapy, and hepatic arterial infusion chemotherapy (HAIC) works and how safe it is for people with hepatocellular carcinoma (HCC) that has grown into the porta…
Phase 2 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
A graft that grows? new vessel may spare infants repeat surgeries
Cure Not yet recruitingThe purpose of this study is to test the safety and performance of a new blood vessel graft, called the ATEV. The graft is designed to reconnect the heart to the lungs and to grow as the child grows, which may eliminate the need for future surgeries.
Phase 1/2 • Sponsor: Joseph Dearani • Aim: Cure
Last updated Aug 27, 2026 00:00 UTC
-
Dye-Guided surgery may spare healthy lymph nodes in esophageal cancer
Disease control Not yet recruitingIn the comprehensive treatment system for esophageal cancer, surgical resection combined with regional lymph node dissection remains the core component for achieving cure in patients with resectable esophageal squamous cell carcinoma (ESCC). The traditional surgical concept holds…
Phase 3 • Sponsor: Fujian Medical University Union Hospital • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Can a Two-Pronged immune attack outsmart stomach cancer?
Disease control Not yet recruitingThis is a multicenter, randomized Phase II window-of-opportunity study evaluating rilvegostomig (AZD2936) in patients with treatment-naïve, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma with PD-L1 CPS ≥1. Rilvegost…
Phase 2 • Sponsor: Vall d'Hebron Institute of Oncology • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Can surgery after drug therapy beat drugs alone for stomach cancer spread?
Disease control Not yet recruitingThe goal of this clinical trial is to learn if radical surgery improves prognosis and quality of life compared with continued standard non-surgical treatment in gastric cancer patients with peritoneal metastasis who have achieved successful conversion therapy. The main questions …
Phase 3 • Sponsor: Hua Huang, MD, PhD • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Can oxygen therapy boost immunotherapy against brain cancer?
Disease control Not yet recruitingThis is a prospective, randomized, open-label, multicenter phase II study. Newly-diagnosed primary glioblastoma patients who have undergone maximal safe resection or biopsy and completed standard concurrent chemoradiotherapy will be enrolled. Subjects will be randomized 1:1 into …
Phase 2 • Sponsor: Wei Jiang • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Can a T-Cell engager open the door to more kidney transplants?
Disease control Not yet recruitingThis investigator-initiated, single-arm, open-label Phase IIa pilot study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of OM336 in highly HLA-sensitized adults with chronic kidney disease awaiting kidney transplantation. The…
Phase 2 • Sponsor: Medical University of Vienna • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Can radiation spare the brain while fighting cancer in the spinal fluid?
Disease control Not yet recruitingThe purpose of this study is to determine the efficacy of BRain-AVOidant proton craniospinal irradiation (BRAVO pCSI) in adult participants with leptomeningeal metastases from solid tumors.
Phase 2 • Sponsor: University of Miami • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can a Two-Drug immunotherapy combo shrink MSS colon cancer before surgery?
Disease control Not yet recruitingThe goal of this clinical trial is to learn if giving two medicines together, porustobart and pembrolizumab, before surgery can treat a common type of colon cancer called microsatellite stable (MSS) colon cancer in adults. This type of cancer can be removed with surgery and has n…
Phase 2 • Sponsor: Solstice Oncology, Inc. • Aim: Disease control
Last updated Sep 09, 2026 15:00 UTC